COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series.
暂无分享,去创建一个
A. Carrá | G. Luetic | N. Deri | J. Rojas | R. Alonso | E. Carnero Contentti | M. Menichini | J. Steinberg | M. Burgos
[1] D. Centonze,et al. Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical Viewpoint , 2021, Current neuropharmacology.
[2] A. Carrá,et al. COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America , 2021, Multiple Sclerosis and Related Disorders.
[3] Meral Mirza,et al. Transient monocular visual impairment as an initial symptom of COVID-19 infection in an individual with multiple sclerosis receiving teriflunomide , 2021, Neurological Sciences.
[4] M. Sahraian,et al. COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review , 2021, Multiple Sclerosis and Related Disorders.
[5] M. Sormani,et al. Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis , 2021, Annals of neurology.
[6] F. Journé,et al. Prevalence and 6‐month recovery of olfactory dysfunction: a multicentre study of 1363 COVID‐19 patients , 2021, Journal of internal medicine.
[7] V. Di Lazzaro,et al. COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review , 2021, Multiple Sclerosis and Related Disorders.
[8] M. Ghasemi-Kasman,et al. Impact of disease‐modifying drugs on the severity of COVID‐19 infection in multiple sclerosis patients , 2020, Journal of medical virology.
[9] M. Zaffaroni,et al. Mild COVID‐19 infection in a group of teriflunomide‐treated patients with multiple sclerosis , 2020, Journal of Neurology.
[10] A. Conte,et al. The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia , 2020, Journal of Neuroimmunology.
[11] M. Trojano,et al. Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide , 2020, Journal of the Neurological Sciences.
[12] C. Louapre,et al. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. , 2020, JAMA neurology.
[13] M. Wattjes,et al. Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse , 2020, Journal of Neurology.
[14] M. Filippi,et al. COVID-19 in teriflunomide-treated patients with multiple sclerosis , 2020, Journal of Neurology.
[15] P. Kuppen,et al. Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile , 2019, Cancer Immunology, Immunotherapy.